CTLA 4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation by Asad Bashey, Bridget Medina, Sue Corringham, Mildred Pasek, Ewa Carrier, Linda Vrooman, Israel Lowy, Scott R. Solomon, Lawrence E. Morris, H. Kent Holland, James R. Mason, Edwin P. Alyea, Robert J. Soiffer, and Edward D. Ball Blood Volume 113(7): 1581 -1588 February 12, 2009 © 2009 by American Society of Hematology
Pneumonitis after retreatment with ipilimumab. Asad Bashey et al. Blood 2009; 113: 1581 -1588 © 2009 by American Society of Hematology
Regression of malignancy in a patient with mantle cell lymphoma. Asad Bashey et al. Blood 2009; 113: 1581 -1588 © 2009 by American Society of Hematology
Regression of malignancy in a patient with HD. CT scans (A, B) and PET scans (C, D) from patient 2517 (dose level 3. 0 mg/kg) showing right hilar adenopathy before (A, C) and 2 months after (B, D) ipilimumab infusion. Asad Bashey et al. Blood 2009; 113: 1581 -1588 © 2009 by American Society of Hematology
Kaplan-Meier plot of overall survival from the time of ipilimumab therapy for all patients (n = 29). Asad Bashey et al. Blood 2009; 113: 1581 -1588 © 2009 by American Society of Hematology
Serum ipilimumab levels after a single infusion of doses from 0. 1 to 3. 0 mg/kg. Asad Bashey et al. Blood 2009; 113: 1581 -1588 © 2009 by American Society of Hematology
Скачать презентацию CTLA 4 blockade with ipilimumab to treat relapse
a0b7c4ee558b16bc7cc9356b52e46bb2.ppt